BioTuesdays

Author - Leonard Zehr

CymaBay
Markets

Roth ups CymaBay price target to $6

Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following...

August 12, 2016
Bio-Path Holdings
Markets

Maxim cuts Bio-Path price target to $2

Maxim Group lowered its price target for Bio-Path Holdings (NASDAQ:BPTH) to $2 from $5, citing the company’s data trough ahead. The stock was changing hands at $1.72 on Wednesday afternoon. Analyst Jason McCarthy writes...

August 10, 2016
Profound Medical Logo
Markets

Mackie starts Profound Medical at speculative buy

Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday. “Relative to all...

August 10, 2016
Galena Biopharma
Markets

Maxim cuts Galena Biopharma price target to $1

Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday. At the end of June, an Independent Data...

August 10, 2016
Omeros
Markets

Maxim cuts Omeros price target to $19

Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday. Analyst Jason Kolbert writes that sales...

August 10, 2016
Sophiris Bio Logo
Markets

Maxim ups Sophiris price target to $6

Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday. As the datasets for topsalysin...

August 10, 2016
Intellia Therapeutics
Markets

Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday. “We believe the current valuation...

August 5, 2016
Pieris Pharmaceuticals
Markets

Roth reinitiates coverage of Pieris Pharma at buy

Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday. “We believe the company’s anticalin platform has broad...

August 5, 2016